Key Highlights

  • Kodiak Sciences (NASDAQ:KOD) traded at USD 93.93 on October 28, 2026, up 52.22% over one month, up 3.06% over one week, up 129.55% over three months and up 236.55% year to date, per published market data.
  • Kodiak Sciences (NASDAQ:KOD) reported Phase 3 DAYBREAK topline results on September 28, 2026 in which Zenkuda and tabirafusp-ted both met their primary endpoints against aflibercept in wet age-related macular degeneration.
  • The stock closed at USD 32.35 on September 25 and trades at USD 93.93, up about 190%, simple arithmetic, and several analysts have raised targets to between USD 96 and USD 145.
  • The company plans a multi-indication biologics license application for Zenkuda in the fourth quarter of 2026, but cash of about USD 126 million supports operations only into 2027, so financing risk is real.

The DAYBREAK Results

On September 28, 2026, the company reported topline results from the DAYBREAK Phase 3 study in wet AMD. Zenkuda (tarcocimab tedromer) met its primary endpoint with a p-value of 0.0007, and tabirafusp-ted met its visual acuity primary endpoint with a p-value of 0.0036 and a key anatomical secondary endpoint with a p-value below 0.0001. About 54% of Zenkuda patients reached a six-month dosing interval under a strict treat-to-dryness standard. Intraocular inflammation was 0%. These are topline figures from a company release, and the full visual acuity distribution is not yet public. In wet AMD, the comparator aflibercept is the long-standing standard of care, so matching it with fewer injections is the commercial goal.

Analyst Targets and the Filing Plan

Published analyst actions followed: LifeSci Capital to USD 145, Jefferies to USD 112, UBS to USD 120, H.C. Wainwright to USD 126 and Goldman Sachs to USD 103 with a Neutral rating. The company plans to file a biologics license application for Zenkuda in the fourth quarter of 2026, covering wet AMD, diabetic retinopathy and retinal vein occlusion, and the topline readout of the PEAK study of KSI-101 is expected in December 2026. Kodiak Sciences (NASDAQ:KOD) is up 129.55% over three months and 236.55% year to date. The implied price a month ago was about USD 61.71, simple arithmetic. Analyst targets are opinions, not forecasts the company controls.

Risks and What to Watch

Kodiak has no commercial product or revenue and reported about USD 126 million of cash at the end of the second quarter, which management says supports operations into 2027, so an equity raise, partnership or royalty deal is likely. Regulators must still review the filing, the strict retreatment standard may not match routine practice and the stock has a beta near 2.2, so swings are large. Watch the filing date, the December PEAK readout and any financing. The 2.86% gain on October 28 shows momentum is intact. This is not advice. A secondary financing after strong data is common for development-stage companies, and it would dilute existing holders.

Where Things Stand

The answer is that Phase 3 DAYBREAK results explain the month. Kodiak Sciences (NASDAQ:KOD) gained 52.22% over a month and about 190% since the September 25 close, as both lead candidates met their primary endpoints on September 28, 2026. The company still needs to file and win approval, and about USD 126 million of cash leaves financing risk. The fourth quarter filing and the December PEAK readout are the next catalysts.